Screening for coronary artery disease in diabetic patients: A commentary by Berman, Daniel S. et al.
EDITORIAL POINT OF VIEW
Screening for coronary artery disease in diabetic
patients: A commentary
Daniel S. Berman, MD,
a,b Alan Rozanski, MD,
c Jamal S. Rana, MD, PhD,
a,b
Leslee J. Shaw, PhD,
d Nathan D. Wong, PhD,
e and James K. Min, MD
f
Diabetes is a major coronary artery disease (CAD)
risk factor which is increasing in prevalence, and com-
monly associated with asymptomatic CAD.
1 Patients
with diabetes without previous myocardial infarction
2 or
cardiovascular disease
3 have been shown to have a
similar prognosis as persons without diabetes but with
prior myocardial infarction or cardiovascular disease.
2
Based on these group and population-based data, dia-
betes is considered a ‘‘CAD risk-equivalent’’ according
to current Framingham Risk Score Adult Treatment
Program III guidelines, and secondary prevention of
CAD is recommended for all adult diabetic patients.
3
However, to date, what has been unresolved is
whether there is additional clinical beneﬁt for routine
screening of individual asymptomatic diabetics for
CAD. In this regard, the recently reported long-term
follow-up from the Diagnostic Imaging in Asymptom-
atic Diabetics (DIAD) trial represents an important ﬁrst
step forward toward answering this question.
4 The
DIAD study examined whether screening of diabetic
patients with SPECT myocardial perfusion imaging
(MPI) could enhance detection of those with high CAD
risk and whether the detection of this CAD risk was
associated with an improvement in clinical outcomes.
In 1123 asymptomatic individuals with type 2 dia-
betes,SPECT-MPIscreeningwascomparedtousualcare.
While rates of hard cardiac events were low in both the
SPECT-MPI (2.7%) and the usual care (3.0%) groups,
SPECT-MPI was nevertheless able to successfully dis-
criminate those with higher likelihood of cardiac events
based upon moderate or large perfusion deﬁcits versus
those with a very low likelihood of future cardiac events
based upon normal perfusion or small perfusion deﬁcits
(2.4% vs. 0.4%, P = 0.001). Despite this discriminatory
ability, however, SPECT-MPI screening was not associ-
ated with an improvement in cardiac outcomes, and the
DIADinvestigatorsconcludedthat‘‘routinescreeningfor
inducible ischemia in asymptomatic patients with type 2
diabetes cannot be advocated.’’
Although we are in agreement with this general
conclusion, we propose below an important role for
SPECT-MPIfortheselectiveevaluationofasymptomatic
patients with diabetes as well as an alternative paradigm
for more effective CAD screening. Numerous prior
studies comparing individuals with and without diabetes
have demonstrated that diabetes is associated with
heightened mortality among patients with ischemic
SPECT-MPI stratiﬁed according to any level of myocar-
dial ischemia.
5,6 Within the DIAD trial, there was
similarlyastepwiseincreaseincumulativecardiacevents
among those with increasing SPECT-MPI abnormality,
paralleling prior experience. In fact, among patients with
atleastmoderateischemia,thehardcardiaceventratewas
12% vs. 2% in the normal scan group. Notably, however,
only33(8%)ofthe561patientswithinthescangrouphad
a moderate perfusion defect or greater, making this a trial
of primarily nonischemic patients. Importantly, this low
frequency of ischemia may help explain why the annu-
alized cardiac event rate was only 0.6% per year in the
DIAD study, thus making it difﬁcult to discern mean-
ingful differences within the SPECT-MPI versus usual
care arm of this trial.
Still, as aforementioned, in contrast to the results of
the current DIAD trial, prior results have suggested that
nonischemic SPECT-MPI patients with diabetes are an
intermediate risk group for clinical events. One likely
explanation is the temporal difference in these follow-up
studies, with the contemporary DIAD study coinciding
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851with a time of increasingly aggressive medical treatment
of diabetes and other CAD risk factors. In support of this
hypothesis is the notable ﬁnding within the DIAD study
of marked increase from baseline to 5 years for use of
aspirin, diabetes control, lipid lowering, and antihyper-
tensive therapies within both the scan and no-scan
groups. This considerable intensiﬁcation in medication
use was undoubtedly inﬂuential in both lowering mor-
tality rates and diluting potential clinical differences
within the two arms of the DIAD trial. Prior studies of
patients tested in an era predating this type of aggressive
medical therapy may have manifested higher clinical
event rates among nonischemic SPECT MPI patients.
As current medical therapy is reducing the risk of
cardiac events in the average asymptomatic diabetic
patient, adjustments are now necessary to redeﬁne a suf-
ﬁciently high-risk asymptomatic diabetic subgroup that
will beneﬁt from stress imaging for ischemia. In this
regard, the application of coronary artery calcium (CAC)
scanningbynoncontrastcomputedtomography(CT)may
represent an important vehicle by which to achieve this
objective.
7 CT coronary calcium scanning is an inex-
pensive test with no injections and very low radiation
exposure. Since CAC is almost exclusively a marker of
atherosclerosis, its assessment provides information
regarding the extent of coronary plaque burden. A sub-
stantial body of evidence has deﬁnitively established that
the Agatston coronary calcium score (CCS)—a widely
used measure of the extent of CAC—provides risk strat-
iﬁcationintheasymptomatic general population,
8-12with
superiority to other imaging screening tests, such as car-
otid intima-medial thickness scanning.
13
Speciﬁc to the assessment of diabetes, CAC mea-
surement provides potent risk stratiﬁcation for asymp-
tomatic diabetics. In a large study of 10,377 patients (903
diabetics, age 57 ± 10 years) who underwent CAC
scanning and were then followed for 5 years for all-cause
mortality, Raggi et al found that for any category of CAC
over zero, there was a stepwise increased mortalityrisk in
individual with diabetes compared to those without, as
shown in Figure 1.
14 Notwithstanding the ability of CAC
to predict incident cardiac risk, the converse also appears
to hold true; namely, individuals with diabetes with a low
CAC score have a very favorable prognosis. Within this
study, among the 39% of diabetics with a CAC score of
\10, the 5-year all-cause death rate was extremely low,
and was similar to rates for those without diabetes with
similar CAC scores.
The recently conducted PREDICT Study was a pro-
spective cohort study of 589 asymptomatic type 2
diabetics (median age 63.1) with no history of cardio-
vascular disease,designed to evaluate CAC as a predictor
of cardiovascular events. CAC was a highly signiﬁcant,
independent predictor of events (P\0.001), with a
doubling in CAC being associated with a 29% increase in
riskofevents.
9CACprovidedgreaterpredictivevaluefor
cardiac events than Framingham Risk Score and UKPDS
risk scores as well as to conventional and novel risk fac-
tors. Of note, 23% of the patients had CAC scores B10,
despite the older age of the population than in most other
reports, and these patients had a 0.2% event rate per year.
Inarelatedstudy,Anandetal
15reportedCACscores
\10 to be present in more than 50% of individuals with
diabetes (age 52 ± 8 years) reﬂecting values similar to
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Figure 1. Cox proportional hazards survival in 10,377 patients undergoing coronary artery calcium
scanning were followed up 5.0 ± 3.5 years for all-cause mortality. Overall, the death rate was 3.5%
and 2.0% for individuals with diabetes and without diabetes (P\0.0001). (Adapted with
permission from J Am Coll Cardiol.
14).
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diabetics which has shown that 30% have a CCS of 0 and
8% have a CCS of 0-9 (unpublished data). We have also
publisheddata showinga fourthof men and nearlyhalf of
women with diabetes have no detectable coronary cal-
cium.
15 This ﬁnding could be of major psychological
import to such patients, and may have favorable impli-
cations for the downstream use of medical resource
utilization (e.g., clinical visits and frequency of sub-
sequent stress testing). A prospective study is needed to
test this possibility.
Among patients who do have CAC, we and others
have also demonstrated a threshold relationship between
the magnitude of CAC and the likelihood of observing
inducible myocardial ischemia. Within general popula-
tions—including our own—this threshold has been
observed to be a CAC score C400. When limited to
asymptomatic nondiabetic patients, we have noted that a
CAC score threshold of 1000 may be more robust for
discriminating those individuals with a low frequency of
inducible ischemia (unpublished observations). Based
upon the extrapolation of data from stress testing, the
CAC threshold of 400 appears appropriate for asymp-
tomatic individuals with diabetes compared to those
without diabetes.
16 The data from Anand et al
15 also
support a CAC score of 400, the threshold for identifying
sufﬁciently high CAD risk as to warrant SPECT-MPI in
asymptomatic diabetics.
A recent consensus statement by Bax et al has
formulated a strategy which purports to improve the
potential cost-effectiveness of screening using CAC
scanning by selectively employing it among those with
high-risk clinical features including other atherosclerotic
vascular disease, microalbuminuria and chronic kidney
disease, abnormal resting ECG, retinopathy, hypergly-
cemia, multiple other cardiac risk factors, and age over
65 years.
17 A further study in this regard by Mazzone
et al reported in 439 asymptomatic individuals with
diabetes that age, systolic blood pressure, male gender,
and triglyceride-rich lipoproteins are predictors of CAC
in diabetics.
18 In their study, measures of adipose tissue
distribution were signiﬁcantly associated with CAC
score, whereas inﬂammatory and metabolic factors were
not. Further study is needed to evaluate which clinical
data may be most useful in tailoring the application of
CAC scanning among asymptomatic diabetics.
At the time that the DIAD study was conceived and
initiated, the relationship between CAC scan results and
SPECT-MPI ﬁndings as well as the utility of using CAC
scanning for risk stratiﬁcation in asymptomatic indi-
viduals with diabetes was not known. These data were
introduced during the follow-up phase of the DIAD trial.
By employing these contemporary ﬁndings, it is now
possible to test a new paradigm for screening
asymptomatic patients with diabetes, the rationale for
which has recently been explored in a comprehensive
editorial by Dr. Beller.
19 This paradigm calls for using
CAC scanning rather than cardiac stress testing as the
ﬁrst-line screening test among such diabetics. It is
expected that approximately one-third of such patients
would have no detectable CAC, and many others would
have CAC scores at levels which obviate the need for
SPECT-MPI. Above a certain CAC threshold (e.g., 400
or possibly 100), SPECT-MPI could be selectively
employed as a means for identifying silent ischemia and
elevated clinical risk. Conceivably, the inclusion of
various clinical parameters such as those suggested by
Bax et al
17 could alter the threshold criteria used to
guide referral to stress testing among diabetic patients
(i.e., selective use of a lower CAC threshold among
those with high-risk clinical features). When high-risk
ischemia is present,
20,21 coronary angiography would be
recommended, based on ﬁndings that this appears to be a
group who beneﬁt from revascularization.
20 In patients
with \10% ischemia, repeat MPI might be appropriate
in 3 years.
22 While it might be of interest to determine
the added value of noninvasive coronary CT angiogra-
phy over CAC scanning in patients with diabetes,
22 such
consideration awaits the publication of evidence that this
added testing would provide sufﬁcient additional value
to be cost-effective.
A major problem with this approach has been that
CAC scanning has not been widely covered by insurance
carriers, generally making it available only in research
studies or to patients who can afford to pay for the
studies on their own. It is noteworthy in this regard that
the Texas Legislature has passed legislation requiring
insurance plans to provide coverage for screening with
the CAC or carotid IMT scans. This coverage require-
ment applies to men ages 46 to 75 and women ages 56 to
75 who are either diabetic or have an intermediate or
higher risk for developing heart disease.
23
In all likelihood, the most of the small number of
patients who had moderate to severe ischemia within the
DIAD study would have been identiﬁed as deserving
selective referral for SPECT-MPI according to this para-
digm, based on prior observation regarding the
relationship of CAC scores among ischemic SPECT-MPI
patients.
24 Many other patients within the DIAD trial,
however,wouldhavebeenselectivelyreferredawayfrom
SPECT-MPIimaging,butwiththeirburdenofunderlying
atherosclerosis and thus long-term risk, better character-
ized by virtue of having undergone CAC scanning. Given
the growing threat posed by the increasing prevalence of
diabetes, testing of algorithms which cost-effectively
select for the identiﬁcation of high-risk asymptomatic
individuals with diabetes is urgently warranted and not
negated by the results of the DIAD trial.
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